# AbbVie Type: Company Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/abbvie Canonical HTML page: https://getbiobrief.com/entity/abbvie ## Timeline - **2029-01-01**: Operational Launch — New facilities expected to come online to support next-gen drug production. - **2026-03-20**: Construction Start — Anticipated ground-breaking for the two new advanced manufacturing sites. - **2026-02-23**: Manufacturing Expansion — AbbVie announces $380 million investment for North Chicago API facilities. - **2026-01-12**: $100B Pledge — AbbVie commits to $100 billion in U.S. R&D and capital investments over the next decade. ## Recent coverage (6 stories) ### How Rinvoq and Skyrizi Will Drive 21.5% EPS Growth at Q2 Print 2026-07-28 01:06:23 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 AbbVie's second-quarter results, expected to show $3.61 EPS, hinge on the continued clinical and commercial success of Rinvoq and Skyrizi. The Apogee deal underscores a deepening immunology pipeline as Humira fades into the rearview. Full story: https://getbiobrief.com/story/abbvie-q2-2026-rinvoq-skyrizi-growth ### Epcoritamab-Lenalidomide Hits Phase 3 PFS Goals: 60% Risk Reduction 2026-07-11 23:08:27 · Sentiment: Very Bullish · Impact: 8/10 · Sources: 3 AbbVie and Genmab's bispecific antibody epcoritamab combined with lenalidomide delivered a hazard ratio of 0.40 in a pivotal DLBCL trial, setting the stage for regulatory filings and a potential second-line market expansion that could challenge CAR-T dominance and redefine the bispecific landscape. Full story: https://getbiobrief.com/story/epcoritamab-lenalidomide-phase3-dlbcl-biotech-abbv-gmab ### UCB Commits $2B to Atlanta Manufacturing Hub to Fuel U.S. Growth 2026-03-24 23:54:36 · Sentiment: Bullish · Impact: 6/10 · Sources: 2 Belgian biopharma leader UCB has announced a massive $2 billion investment to construct a new manufacturing facility in suburban Atlanta, Georgia. The project is expected to create 330 high-tech jobs and significantly enhance the company's production capacity for its growing immunology and neurology portfolios. Full story: https://getbiobrief.com/story/ucb-atlanta-manufacturing-expansion-2-billion ### RBC Capital Initiates AbbVie Coverage with Outperform Rating 2026-02-27 14:46:31 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 RBC Capital has launched coverage of pharmaceutical giant AbbVie with an Outperform rating, signaling confidence in the company's growth trajectory. The initiation suggests that market concerns regarding biosimilar competition for Humira are overstated as newer immunology assets gain significant market share. Full story: https://getbiobrief.com/story/rbc-capital-abbvie-outperform-rating-analysis ### Savara vs. Enanta: Divergent Paths in Rare Respiratory and Virology Markets 2026-02-27 03:44:21 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 A comparative analysis of Savara and Enanta Pharmaceuticals reveals a stark contrast between a de-risked rare disease specialist and a virology firm navigating a pipeline transition. While Savara gains momentum from Phase 3 success in aPAP, Enanta continues to leverage its royalty-based financial foundation to fund high-stakes antiviral trials. Full story: https://getbiobrief.com/story/savara-enanta-biotech-comparison-2026 ### AbbVie Commits $380M to U.S. Manufacturing in $100B Reshoring Push 2026-02-25 00:14:40 · Sentiment: Bullish · Impact: 7/10 · Sources: 3 AbbVie has announced a $380 million investment to expand its manufacturing capabilities in North Chicago, Illinois, marking the first major step in a decade-long $100 billion commitment to U.S. research and development. The move aligns with federal efforts to localize pharmaceutical supply chains and reduce drug prices through direct-to-patient initiatives like TrumpRx. Full story: https://getbiobrief.com/story/abbvie-380-million-us-manufacturing-investment --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.